Zhejiang Medicine’s ARX305 Initiates Phase II Clinical Trial
March 6, 2026
Source: drugdu
30
On the evening of March 5th that Zhejiang Medicine...(600216) issued an announcement stating that its subsidiary, Zhejiang Xinma Biopharmaceutical Co., Ltd. (hereinafter referred to as "Xinma Bio"), has initiated a single-arm, open-label phase II clinical study on the efficacy and safety of its injectable recombinant humanized anti-CD70 monoclonal antibody-AS269 conjugate (ARX305) for relapsed/refractory lymphoma.
Zhejiang Medicine stated that the recombinant humanized anti-CD70 monoclonal antibody-AS269 conjugate for injection (ARX305) is a new generation monoclonal antibody-drug conjugate jointly developed by Newcode Biotech and Ambrx, Inc. of the United States, under a "Cooperative Development and Licensing Agreement" signed on October 22, 2019. It is used to treat advanced tumors expressing CD70 and belongs to innovative biotechnology drugs.
https://finance.eastmoney.com/a/202603053663319462.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Anglikang Adenosylcobalamin Capsules Obtain Drug Registration Certificate March 6, 2026
- Two Minoxidil Topical Solution Applications from its Subsidiary Approved March 6, 2026
- Indacaterol Mometasone Inhalation Powder Clinical Trial Approved for Asthma Treatment March 6, 2026
- Harsco Pharmaceutical’s innovative drug HSK50042 tablets receive clinical approval for a new indication March 6, 2026
- Clinical trial application for HLX97 approved by the National Medical Products Administration March 6, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
